Evaluation of the effect of vitamin D before percutaneous coronary intervention in the prevention of cardiovascular complications

Phase 3

• Conditions: Condition 1: Major adverse cardiovascular events. Condition 2: Precutaneous coronary intervention. Condition 3: Unstable angina.; Abnormal result of cardiovascular function study, unspecified; Presence of coronary angioplasty implant and graft; Atherosclerotic heart disease of native coronary artery with unstable angina pectoris; R94.30; Z95.5; I25.110

• Registration Number: IRCT20210228050528N1
• Lead Sponsor: Zanjan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

Patients with unstable angina who are candidates for PCI
Patients with deficient serum levels of vitamin D

Exclusion Criteria

Previous history of myocardial infarction
Previous history of revascularization therapy interventions
Patients with a previous history of CABG
Patients with failed PCI
Simultaneous involvement of valvular disorders
Take vitamin D, calcium or omega-3 supplements in the last 3 months
Patients with hypercalcemia, nephrolithiasis, sarcoidosis, malabsorption syndromes
Chronic underlying diseases such as liver, kidney or rheumatic disorders
Pregnancy and lactation
Having malignancies
History of receiving corticosteroids or immunosuppressants in the last 6 months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of myocardial infarction cases. Timepoint: 3 and 6 months later. Method of measurement: ECG and echocardiography.;Number of revascularization cases in re hospitalization. Timepoint: 3 and 6 months later. Method of measurement: ECG and echocardiography.

Secondary Outcome Measures

Name	Time	Method
Readmission rate. Timepoint: 3 and 6 months later. Method of measurement: ECG and echocardiography.;Mortality rate. Timepoint: 3 and 6 months later. Method of measurement: In-person and telephone follow-up.;Cardiac function. Timepoint: 3 and 6 months later. Method of measurement: In-person follow-up.